Gabrielle is a Philadelphia-based Scientific Support Manager who joined Datwyler Pharma Packaging in 2022. From 2015 to 2019, she attended Widener University and completed her Bachelors' and Masters' degrees in Biomedical Engineering. She has since worked in the pharmaceutical packaging industry, helping major drug companies determine how to safely and effectively package their drug products. Gabrielle has taken a special interest in many related topics, including the process of PERFECTing delivery systems, as well as the benefits of increased degrees of automation in the manufacturing process.

Xuefang is a digital strategy lead at Takeda Pharmaceuticals. Xuefang has 10 years of experience working in pharma companies across medical device development and digital health sciences.

TBD

With a comprehensive background in drug delivery sciences and biomaterial design spanning six years, Dr Eileen Sadeghi has developed a strong foundation of expertise in the field. Dr Sadeghi earned her PhD in Chemical and Biological engineering from Tufts University, where her research focused on the design and synthesis of smart polymers, specifically targeting the separation of pharmaceuticals based on their chemical structure. This pioneering work, chemoselective membranes, has been recognized and featured in esteemed journals. Notably, it was acknowledged as one of the "50 discoveries looking forward to the next 50 years of innovation in engineering" by The Bridge 50th Anniversary Issue, published by the National Academy of Engineering in January 2021. Additionally, Dr Sadeghi patented a new approach for fabrication of ultrathin, multifunctional hydrogel selective layers. She was honored to receive the Outstanding Academic Scholarship from the School of Engineering, distinguishing these efforts among all engineering schools. Continuing her pursuit of scientific excellence, Dr Sadeghi embarked on a postdoctoral research position at the Langer lab at MIT. Here, her primary focus revolved around the development of nano/microparticles for vaccines and adjuvants, with the overarching goal of enhancing vaccination strategies. She successfully led two prominent projects funded by the Gates Foundation, which aimed to achieve mucosal immunity through the peripheral administration of adjuvant nanoparticles and the creation of self-boosting vaccine microparticles. Currently, Dr Sadeghi holds a Senior Scientist II position at Abbvie in the Drug Delivery and Biomaterial Department. Her expertise lies in the sustained delivery of small molecules for the treatment of back of the eye diseases. Additionally, she has been spearheading the genetic medicine effort for ocular applications, further expanding my knowledge and proficiency in this rapidly evolving field. Throughout my career, Dr Sadeghi has gained extensive experience in executing innovative drug delivery platforms tailored to a broad spectrum of therapeutics, including small molecules, active biologics such as vaccines, proteins, and neurotoxins, as well as nucleic acids.

TBA

Sriman is the head of diagnostics, connected devices, and packaging at Takeda Pharmaceuticals. His prior work experience includes working at GlaxoSmithKline, J&J, and a few other companies. He is a Mechanical Engineer with post-graduation in Packaging, Plastics, and Financial management. He has several global awards to his credit and has presented at conferences on devices and packaging. Sriman is an avid traveler and loves reading.

As Vice President of Innovative Health & Advocacy, Staci is charged with creating a new organizational pillar that delivers an integrated, differentiated and superior patient, site, health authority and industry-leading experience for J&J’s clinical trials. She is accountable for a global team that actively seeks to understand all elements of our external stakeholders, critical to the future success and integrate those understandings into a comprehensive innovative strategy for implementation in protocol design, operational execution, and speed to market. Recently, Staci provided overall leadership and direction for the organizations portfolio delivery operations for the following therapeutic areas (TAs): Neuroscience, Cardiovascular & Metabolism, Retinal, Infectious Diseases, and Vaccines. Additionally, she serves as the senior global functional leader for all TAs, including Immunology and Oncology for site feasibility, patient recruitment/retention and diversity in clinical trials.

She came to Johnson & Johnson from Regeneron Pharmaceuticals where Staci led a diverse set of operational groups including clinical drug supply, start-up and compliance. Having held various supply chain related positions with increasing responsibility levels, while at Pharmaceutical Product Development (PPD), a global contract service provider that provides services to the bio-pharmaceutical and device sectors, Staci had global P&L responsibility of the localized supply chain operations encompassing 12 countries. She also led the build-out and opening of distribution centers in Ireland, South Africa, and Brazil. Staci started her career as a protocol specialist at the National Cancer Institute (NCI), which is part of the National Institute of Health in Washington, DC.

Graduating from George Mason University in Virginia, Staci was a six-time NCAA Division I Track & Field All American. She received an Executive MBA from Fordham University.

Active in several professional and community-based organizations, Staci is a founding member of Chief, private network for professional women, the National Coalition of 100 Black Women (NCBW100), and National Black MBA Association. Additionally, she is a member of the Healthcare Businesswomen’s Institute where she is an Executive Circle of Advisors participant, the Drug Information Association and Black Women on Boards.

Staci’s family includes her husband Joe and her three sons Jacob, Jordan, and Justin.

As a trained data scientist and biotechnologist, Mr Biswajit specializes in leveraging the transformative power of data to drive scientific discoveries. With over 17 years of dynamic experience in the healthcare industry, Mr Biswajit garnered a sterling reputation as a versatile, hands-on techno-functional leader, with an exemplary proficiency in data science, Clinical data operations, stats and programming, Real World Evidence, RPA and Six Sigma methodologies.

Fueled by his deep understanding of clinical data operations, statistics, and programming, Mr Biswajit also carries a keen interest in data exploration. He leverages top-tier tools like R Shiny and Python to parse through complex data networks, unearthing crucial insights that power decisive clinical advancements.

Mr Biswajit tenure is marked with leading a multitude of projects, successfully translating intricate business needs into inventive strategies that have consistently yielded notable results. His expertise includes overseeing an array of innovative submission and non-submission trials, such as interventional, non-interventional studies, Real-World Evidence (RWE), and health economics and outcome research (HEOR), where he handles everything from concept design to data acquisition and analysis strategies.

At the heart of Mr Biswajit’s prowess lies ground-breaking work in data linkage through tokenization. By binding data from diverse sources, he has been able to generate an encompassing and comprehensive view of patient health journeys, thus accelerating evidence generation.

As a passionate advocate for technology, he dedicated to improving patient outcomes and driving healthcare innovation. Mr Biswajit’s portfolio includes the successful implementation of purpose-fit digital health solutions such as wearables and sensors and leading the charge in adopting electronic clinical outcome assessments (eCOA).

Mr Biswajit brings with a wealth of experience, passion, and a deep commitment to using data science as a catalyst for innovative advancements in healthcare for the patients.

Varun Kapoor, PhD, is the Senior Director of Translational Medicine at Coherus Biosciences. He brings in more than 10 years of research and development experience in immuno-oncology therapies to help establish and advance translational and biomarker strategies. He completed his post-doctoral training in the cancer-immunology department at Genentech Inc. and earned his doctoral degree in immunology-virology from University of Massachusetts Medical School, Worcester. He believes that translational research holds the key to success of future immuno-oncology trials. He is passionate about his work as it gives him an opportunity to see drug discovery translate into clinical benefit for patients.

TBA